18. Nakagawa T, Johnson RJ, Andres-Hernando A, Roncal-Jimenez C, SanchezLozada LG, Tolan DR, et al. Fructose Production and Metabolism in the
Kidney. J Am Soc Nephrol (2020) 31(5):898–906. doi: 10.1681/ASN.
2019101015
19. Chen Z, Liu M, Li L, Chen L. Involvement of the Warburg Effect in NonTumor Diseases Processes. J Cell Physiol (2018) 233(4):2839–49. doi: 10.1002/
jcp.25998
20. Aoyama M, Isshiki K, Kume S, Chin-Kanasaki M, Araki H, Araki S, et al.
Fructose Induces Tubulointerstitial Injury in the Kidney of Mice. Biochem
Biophys Res Commun (2012) 419(2):244–9. doi: 10.1016/j.bbrc.2012.02.001
21. Cirillo P, Gersch MS, Mu W, Scherer PM, Kim KM, Gesualdo L, et al.
K e t o h e x o k i n as e - D e p e n d e n t M e t a b o l i s m o f F r u c t o s e I n d uc e s
Proinflammatory Mediators in Proximal Tubular Cells. J Am Soc Nephrol
(2009) 20(3):545–53. doi: 10.1681/ASN.2008060576
22. Glushakova O, Kosugi T, Roncal C, Mu W, Heinig M, Cirillo P, et al. Fructose
Induces the Inflammatory Molecule ICAM-1 in Endothelial Cells. J Am Soc
Nephrol (2008) 19(9):1712–20. doi: 10.1681/ASN.2007121304
23. Shinozaki K, Kashiwagi A, Nishio Y, Okamura T, Yoshida Y, Masada M, et al.
Abnormal Biopterin Metabolism is a Major Cause of Impaired EndotheliumDependent Relaxation Through Nitric Oxide/O2- Imbalance in InsulinResistant Rat Aorta. Diabetes (1999) 48(12):2437–45. doi: 10.2337/
diabetes.48.12.2437
24. Nakagawa T. Uncoupling of the VEGF-Endothelial Nitric Oxide Axis in
Diabetic Nephropathy: An Explanation for the Paradoxical Effects of VEGF in
Renal Disease. Am J Physiol Renal Physiol (2007) 292(6):F1665–72. doi:
10.1152/ajprenal.00495.2006
25. Nakagawa T, Tanabe K, Croker BP, Johnson RJ, Grant MB, Kosugi T, et al.
Endothelial Dysfunction as a Potential Contributor in Diabetic Nephropathy.
Nat Rev Nephrol (2011) 7(1):36–44. doi: 10.1038/nrneph.2010.152
26. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, et al.
Hyperuricemia Induces Endothelial Dysfunction. Kidney Int (2005) 67
(5):1739–42. doi: 10.1111/j.1523-1755.2005.00273.x
27. Sanchez-Lozada LG, Lanaspa MA, Cristobal-Garcia M, Garcia-Arroyo F, Soto
V, Cruz-Robles D, et al. Uric Acid-Induced Endothelial Dysfunction is
Associated With Mitochondrial Alterations and Decreased Intracellular
ATP Concentrations. Nephron Exp Nephrol (2012) 121(3-4):e71–8. doi:
10.1159/000345509
28. Brezis M, Rosen S. Hypoxia of the Renal Medulla–Its Implications for Disease.
N Engl J Med (1995) 332(10):647–55. doi: 10.1056/NEJM199503093321006
29. Nangaku M. Chronic Hypoxia and Tubulointerstitial Injury: A Final
Common Pathway to End-Stage Renal Failure. J Am Soc Nephrol (2006) 17
(1):17–25. doi: 10.1681/ASN.2005070757
30. Grimm C, Wenzel A, Groszer M, Mayser H, Seeliger M, Samardzija M, et al.
HIF-1-Induced Erythropoietin in the Hypoxic Retina Protects Against LightInduced Retinal Degeneration. Nat Med (2002) 8(7):718–24. doi: 10.1038/
nm723
31. Liu J, Wei Q, Guo C, Dong G, Liu Y, Tang C, et al. Hypoxia, HIF, and
Associated Signaling Networks in Chronic Kidney Disease. Int J Mol Sci
(2017) 18(5):950. doi: 10.3390/ijms18050950
32. Park TJ, Reznick J, Peterson BL, Blass G, Omerbasic D, Bennett NC, et al.
Fructose-Driven Glycolysis Supports Anoxia Resistance in the Naked MoleRat. Science (2017) 356(6335):307–11. doi: 10.1126/science.aab3896
33. Mirtschink P, Krishnan J, Grimm F, Sarre A, Horl M, Kayikci M, et al. HIFDriven SF3B1 Induces KHK-C to Enforce Fructolysis and Heart Disease.
Nature (2015) 522(7557):444–9. doi: 10.1038/nature14508
34. Brownlee M. Biochemistry and Molecular Cell Biology of Diabetic
Complications. Nature (2001) 414(6865):813–20. doi: 10.1038/414813a
35. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, et al.
Normalizing Mitochondrial Superoxide Production Blocks Three Pathways of
Hyperglycaemic Damage. Nature (2000) 404(6779):787–90. doi: 10.1038/
35008121
Japan Society for the Promotion of Science (21K10284).
1. Morita M, Kanasaki K. Sodium-Glucose Cotransporter-2 Inhibitors for
Diabetic Kidney Disease: Targeting Warburg Effects in Proximal Tubular
Cells. Diabetes Metab (2020) 46(5):353–61. doi: 10.1016/j.diabet.2020.06.005
2. Huang Z, Hong Q, Zhang X, Xiao W, Wang L, Cui S, et al. Aldose Reductase
Mediates Endothelial Cell Dysfunction Induced by High Uric Acid
Concentrations. Cell Commun Signal (2017) 15(1):3. doi: 10.1186/s12964016-0158-6
3. Srivastava SK, Ramana KV, Bhatnagar A. Role of Aldose Reductase and
Oxidative Damage in Diabetes and the Consequent Potential for Therapeutic
Options. Endocr Rev (2005) 26(3):380–92. doi: 10.1210/er.2004-0028
4. Yamauchi A, Miyai A, Shimada S, Minami Y, Tohyama M, Imai E, et al.
Localization and Rapid Regulation of Na+/myo-inositol Cotransporter in Rat
Kidney. J Clin Invest (1995) 96(3):1195–201. doi: 10.1172/JCI118151
5. Andres-Hernando A, Li N, Cicerchi C, Inaba S, Chen W, Roncal-Jimenez C, et al.
Protective Role of Fructokinase Blockade in the Pathogenesis of Acute Kidney
Injury in Mice. Nat Commun (2017) 8:14181. doi: 10.1038/ncomms14181
6. Lanaspa MA, Ishimoto T, Cicerchi C, Tamura Y, Roncal-Jimenez CA, Chen
W, et al. Endogenous Fructose Production and Fructokinase Activation
Mediate Renal Injury in Diabetic Nephropathy. J Am Soc Nephrol (2014) 25
(11):2526–38. doi: 10.1681/ASN.2013080901
7. Bjornstad P, Lanaspa MA, Ishimoto T, Kosugi T, Kume S, Jalal D, et al.
Fructose and Uric Acid in Diabetic Nephropathy. Diabetologia (2015) 58
(9):1993–2002. doi: 10.1007/s00125-015-3650-4
8. Wang M, Chen WY, Zhang J, Gobejishvili L, Barve SS, McClain CJ, et al.
Elevated Fructose and Uric Acid Through Aldose Reductase Contribute to
Experimental and Human Alcoholic Liver Disease. Hepatology (2020) 72
(5):1617–37. doi: 10.1002/hep.31197
9. Francey C, Cros J, Rosset R, Creze C, Rey V, Stefanoni N, et al. The ExtraSplanchnic Fructose Escape After Ingestion of a Fructose-Glucose Drink: An
Exploratory Study in Healthy Humans Using a Dual Fructose Isotope Method.
Clin Nutr ESPEN (2019) 29:125–32. doi: 10.1016/j.clnesp.2018.11.008
10. Lanaspa MA, Ishimoto T, Li N, Cicerchi C, Orlicky DJ, Ruzycki P, et al.
Endogenous Fructose Production and Metabolism in the Liver Contributes to
the Development of Metabolic Syndrome. Nat Commun (2013) 4:2434. doi:
10.1038/ncomms3929
11. Lanaspa MA, Kuwabara M, Andres-Hernando A, Li N, Cicerchi C, Jensen T,
et al. High Salt Intake Causes Leptin Resistance and Obesity in Mice by
Stimulating Endogenous Fructose Production and Metabolism. Proc Natl
Acad Sci USA (2018) 115(12):3138–43. doi: 10.1073/pnas.1713837115
12. Johnson RJ, Perez-Pozo SE, Sautin YY, Manitius J, Sanchez-Lozada LG, Feig
DI, et al. Hypothesis: Could Excessive Fructose Intake and Uric Acid Cause
Type 2 Diabetes? Endocr Rev (2009) 30(1):96–116. doi: 10.1210/er.2008-0033
13. Nakagawa T, Tuttle KR, Short RA, Johnson RJ. Hypothesis: Fructose-Induced
Hyperuricemia as a Causal Mechanism for the Epidemic of the Metabolic
Syndrome. Nat Clin Pract Nephrol (2005) 1(2):80–6. doi: 10.1038/
ncpneph0019
14. Gersch MS, Mu W, Cirillo P, Reungjui S, Zhang L, Roncal C, et al. Fructose, But
Not Dextrose, Accelerates the Progression of Chronic Kidney Disease. Am J
Physiol Renal Physiol (2007) 293(4):F1256–61. doi: 10.1152/ajprenal.00181.2007
15. Nakayama T, Kosugi T, Gersch M, Connor T, Sanchez-Lozada LG, Lanaspa
MA, et al. Dietary Fructose Causes Tubulointerstitial Injury in the Normal Rat
Kidney. Am J Physiol Renal Physiol (2010) 298(3):F712–20. doi: 10.1152/
ajprenal.00433.2009
16. Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, et al. A
Causal Role for Uric Acid in Fructose-Induced Metabolic Syndrome. Am J Physiol
Renal Physiol (2006) 290(3):F625–31. doi: 10.1152/ajprenal.00140.2005
17. Nakagawa T, Lanaspa MA, Millan IS, Fini M, Rivard CJ, Sanchez-Lozada LG,
et al. Fructose Contributes to the Warburg Effect for Cancer Growth. Cancer
Metab (2020) 8:16. doi: 10.1186/s40170-020-00222-9
Frontiers in Immunology | www.frontiersin.org
June 2021 | Volume 12 | Article 694457
Nakagawa et al.
Fructose Causes Chronic Kidney Disease
36. Giacco F, Brownlee M. Oxidative Stress and Diabetic Complications. Circ Res
(2010) 107(9):1058–70. doi: 10.1161/CIRCRESAHA.110.223545
37. Naudi A, Jove M, Ayala V, Cassanye A, Serrano J, Gonzalo H, et al. Cellular
Dysfunction in Diabetes as Maladaptive Response to Mitochondrial Oxidative
Stress. Exp Diabetes Res (2012) 2012:696215. doi: 10.1155/2012/696215
38. Sharma K. Mitochondrial Hormesis and Diabetic Complications. Diabetes
(2015) 64(3):663–72. doi: 10.2337/db14-0874
39. Akude E, Zherebitskaya E, Chowdhury SK, Smith DR, Dobrowsky RT,
Fernyhough P. Diminished Superoxide Generation Is Associated With
Respiratory Chain Dysfunction and Changes in the Mitochondrial
Proteome of Sensory Neurons From Diabetic Rats. Diabetes (2011) 60
(1):288–97. doi: 10.2337/db10-0818
40. Herlein JA, Fink BD, O’Malley Y, Sivitz WI. Superoxide and Respiratory
Coupling in Mitochondria of Insulin-Deficient Diabetic Rats. Endocrinology
(2009) 150(1):46–55. doi: 10.1210/en.2008-0404
41. Bugger H, Boudina S, Hu XX, Tuinei J, Zaha VG, Theobald HA, et al. Type 1
Diabetic Akita Mouse Hearts Are Insulin Sensitive But Manifest Structurally
Abnormal Mitochondria That Remain Coupled Despite Increased Uncoupling
Protein 3. Diabetes (2008) 57(11):2924–32. doi: 10.2337/db08-0079
42. Sas KM, Kayampilly P, Byun J, Nair V, Hinder LM, Hur J, et al. Tissue-Specific
Metabolic Reprogramming Drives Nutrient Flux in Diabetic Complications.
JCI Insight (2016) 1(15):e86976. doi: 10.1172/jci.insight.86976
43. Sharma K, Karl B, Mathew AV, Gangoiti JA, Wassel CL, Saito R, et al.
Metabolomics Reveals Signature of Mitochondrial Dysfunction in Diabetic
Kidney Disease. J Am Soc Nephrol (2013) 24(11):1901–12. doi: 10.1681/
ASN.2013020126
44. Torres VE, Harris PC, Pirson Y. Autosomal Dominant Polycystic Kidney
Disease. Lancet (2007) 369(9569):1287–301. doi: 10.1016/S0140-6736(07)
60601-1
45. Rowe I, Chiaravalli M, Mannella V, Ulisse V, Quilici G, Pema M, et al.
Defective Glucose Metabolism in Polycystic Kidney Disease Identifies a New
Therapeutic Strategy. Nat Med (2013) 19(4):488–93. doi: 10.1038/nm.3092
46. Chiaravalli M, Rowe I, Mannella V, Quilici G, Canu T, Bianchi V, et al. 2Deoxy-D-Glucose Ameliorates PKD Progression. J Am Soc Nephrol (2016) 27
(7):1958–69. doi: 10.1681/ASN.2015030231
47. Ding H, Jiang L, Xu J, Bai F, Zhou Y, Yuan Q, et al. Inhibiting Aerobic
Glycolysis Suppresses Renal Interstitial Fibroblast Activation and Renal
Fibrosis. Am J Physiol Renal Physiol (2017) 313(3):F561–75. doi: 10.1152/
ajprenal.00036.2017
48. Lan R, Geng H, Singha PK, Saikumar P, Bottinger EP, Weinberg JM, et al.
Mitochondrial Pathology and Glycolytic Shift During Proximal Tubule
Atrophy After Ischemic AKI. J Am Soc Nephrol (2016) 27(11):3356–67. doi:
10.1681/ASN.2015020177
49. Van Schaftingen E, Detheux M, Veiga da Cunha M. Short-Term Control of
Glucokinase Activity: Role of a Regulatory Protein. FASEB J (1994) 8(6):414–
9. doi: 10.1096/fasebj.8.6.8168691
50. Agius L, Peak M. Intracellular Binding of Glucokinase in Hepatocytes and
Translocation by Glucose, Fructose and Insulin. Biochem J (1993) 296(Pt
3):785–96. doi: 10.1042/bj2960785
51. Brown KS, Kalinowski SS, Megill JR, Durham SK, Mookhtiar KA. Glucokinase
Regulatory Protein may Interact With Glucokinase in the Hepatocyte
Nucleus. Diabetes (1997) 46(2):179–86. doi: 10.2337/diabetes.46.2.179
52. Niculescu L, Veiga-da-Cunha M, Van Schaftingen E. Investigation on the
Mechanism by Which Fructose, Hexitols and Other Compounds Regulate the
Translocation of Glucokinase in Rat Hepatocytes. Biochem J (1997) 321( Pt
1):239–46. doi: 10.1042/bj3210239
53. Dekkers CCJ, Gansevoort RT. Sodium-Glucose Cotransporter 2 Inhibitors:
Extending the Indication to Non-Diabetic Kidney Disease? Nephrol Dial
Transpl (2020) 35(Suppl 1):i33–42. doi: 10.1093/ndt/gfz264
54. Nespoux J, Vallon V. Renal Effects of SGLT2 Inhibitors: An Update. Curr
Opin Nephrol Hypertens (2020) 29(2):190–8. doi: 10.1097/MNH.
0000000000000584
55. Cai T, Ke Q, Fang Y, Wen P, Chen H, Yuan Q, et al. Sodium-Glucose
Cotransporter 2 Inhibition Suppresses HIF-1a-Mediated Metabolic Switch
From Lipid Oxidation to Glycolysis in Kidney Tubule Cells of Diabetic Mice.
Cell Death Dis (2020) 11(5):390. doi: 10.1038/s41419-020-2544-7
56. Li J, Liu H, Takagi S, Nitta K, Kitada M, Srivastava SP, et al. Renal Protective
Effects of Empagliflozin Via Inhibition of EMT and Aberrant Glycolysis in
Frontiers in Immunology | www.frontiersin.org
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
Proximal Tubules. JCI Insight (2020) 5(6):e129034. doi: 10.1172/
jci.insight.129034
Abbas NAT, El Salem A, Awad MM. Empagliflozin, SGLT2 Inhibitor,
Attenuates Renal Fibrosis in Rats Exposed to Unilateral Ureteric
Obstruction: Potential Role of Klotho Expression. Naunyn Schmiedebergs
Arch Pharmacol (2018) 391(12):1347–60. doi: 10.1007/s00210-018-1544-y
Li Q, Li Y, Liang L, Li J, Luo D, Liu Q, et al. Klotho Negatively Regulated
Aerobic Glycolysis in Colorectal Cancer Via ERK/HIF1a Axis. Cell Commun
Signal (2018) 16(1):26. doi: 10.1186/s12964-018-0241-2
Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, et al. Shift
to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2
Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Diabetes (2016) 65(5):1190–5. doi: 10.2337/db15-1356
Vidali S, Aminzadeh S, Lambert B, Rutherford T, Sperl W, Kofler B, et al.
Mitochondria: The Ketogenic Diet–a Metabolism-Based Therapy. Int J
Biochem Cell Biol (2015) 63:55–9. doi: 10.1016/j.biocel.2015.01.022
Mudaliar S, Alloju S, Henry RR. Can a Shift in Fuel Energetics Explain the
Beneficial Cardiorenal Outcomes in the EMPA-REG Outcome Study? A Unifying
Hypothesis Diabetes Care (2016) 39(7):1115–22. doi: 10.2337/dc16-0542
Packer M. Interplay of Adenosine Monophosphate-Activated Protein Kinase/
Sirtuin-1 Activation and Sodium Influx Inhibition Mediates the Renal Benefits
of Sodium-Glucose Co-Transporter-2 Inhibitors in Type 2 Diabetes: A Novel
Conceptual Framework. Diabetes Obes Metab (2020) 22(5):734–42. doi:
10.1111/dom.13961
Phadke G, Kaushal A, Tolan DR, Hahn K, Jensen T, Bjornstad P, et al. Osmotic
Nephrosis and Acute Kidney Injury Associated With Sglt2 Inhibitor Use: A Case
Report. Am J Kidney Dis (2020) 76(1):144–7. doi: 10.1053/j.ajkd.2020.01.015
O’Neill LA, Hardie DG. Metabolism of Inflammation Limited by AMPK and
Pseudo-Starvation. Nature (2013) 493(7432):346–55. doi: 10.1038/nature11862
Viola A, Munari F, Sanchez-Rodriguez R, Scolaro T, Castegna A. The
Metabolic Signature of Macrophage Responses. Front Immunol (2019)
10:1462. doi: 10.3389/fimmu.2019.01462
Malide D, Davies-Hill TM, Levine M, Simpson IA. Distinct Localization of GLUT1, -3, and -5 in Human Monocyte-Derived Macrophages: Effects of Cell Activation.
Am J Physiol (1998) 274(3):E516–26. doi: 10.1152/ajpendo.1998.274.3.E516
Jones N, Blagih J, Zani F, Rees A, Hill DG, Jenkins BJ, et al. Fructose
Reprogrammes Glutamine-Dependent Oxidative Metabolism to Support
LPS-induced Inflammation. Nat Commun (2021) 12(1):1209. doi: 10.1038/
s41467-021-21461-4
Choe JY, Kim SK. Quercetin and Ascorbic Acid Suppress Fructose-Induced
NLRP3 Inflammasome Activation by Blocking Intracellular Shuttling of
TXNIP in Human Macrophage Cell Lines. Inflammation (2017) 40(3):980–
94. doi: 10.1007/s10753-017-0542-4
Palsson-McDermott EM, O’Neill LA. The Warburg Effect Then and Now:
From Cancer to Inflammatory Diseases. Bioessays (2013) 35(11):965–73. doi:
10.1002/bies.201300084
Karmaus PWF, Herrada AA, Guy C, Neale G, Dhungana Y, Long L, et al.
Critical Roles of mTORC1 Signaling and Metabolic Reprogramming for MCSF-mediated Myelopoiesis. J Exp Med (2017) 214(9):2629–47. doi: 10.1084/
jem.20161855
Duran RV, Oppliger W, Robitaille AM, Heiserich L, Skendaj R, Gottlieb E,
et al. Glutaminolysis Activates Rag-mTORC1 Signaling. Mol Cell (2012) 47
(3):349–58. doi: 10.1016/j.molcel.2012.05.043
Wilson DF, Rumsey WL, Green TJ, Vanderkooi JM. The Oxygen Dependence
of Mitochondrial Oxidative Phosphorylation Measured by a New Optical
Method for Measuring Oxygen Concentration. J Biol Chem (1988) 263
(6):2712–8. doi: 10.1016/S0021-9258(18)69126-4
Semba H, Takeda N, Isagawa T, Sugiura Y, Honda K, Wake M, et al. HIF1alpha-PDK1 Axis-Induced Active Glycolysis Plays an Essential Role in
Macrophage Migratory Capacity. Nat Commun (2016) 7:11635. doi:
10.1038/ncomms11635
Conflict of Interest: ML, LS-L and RJ have equity in a start-up company
developing fructokinase inhibitors (Colorado Research Partners LLC). TN and
RJ also have equity with XORTX therapeutics which is developing novel xanthine
oxidase inhibitors. RJ is also a consultant for Horizon Pharmaceuticals, Inc. BR-I is
a recipient of the Cátedra Salvador Zubirán, Universidad Nacional de México and
Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán, Ciudad de
June 2021 | Volume 12 | Article 694457
Nakagawa et al.
Fructose Causes Chronic Kidney Disease
Copyright © 2021 Nakagawa, Sanchez-Lozada, Andres-Hernando, Kojima,
Kasahara, Rodriguez-Iturbe, Bjornstad, Lanaspa and Johnson. This is an openaccess article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply with
these terms.
México, Mexico. PB has acted as a consultant for AstraZeneca, Bayer, BristolMyers Squibb, Boehringer Ingelheim, Eli-Lilly, Sanofi, Novo Nordisk, and
Horizon Pharma. PB serves on the advisory boards of AstraZeneca, Boehringer
Ingelheim, Novo Nordisk and XORTX.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Frontiers in Immunology | www.frontiersin.org
June 2021 | Volume 12 | Article 694457
...